U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06862869) titled 'Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy' on Feb. 20.
Brief Summary: This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
Study Start Date: March 15
Study Type: OBSERVATIONAL
Condition:
Carcinoma, Non-Small-Cell Lung
Intervention:
DRUG: Alectinib
Participants will have received alectinib adjuvant treatment for re...